# Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

> **NCT04810962** · PHASE3 · COMPLETED · sponsor: **Formosa Pharmaceuticals, Inc.** · enrollment: 370 (actual)

## Conditions studied

- Ocular Inflammation and Pain After Cataract Surgery

## Interventions

- **DRUG:** APP13007, 0.05%
- **DRUG:** Matching Vehicle Placebo for APP13007, 0.05%

## Key facts

- **NCT ID:** NCT04810962
- **Lead sponsor:** Formosa Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-16
- **Primary completion:** 2022-07-06
- **Final completion:** 2022-07-06
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2023-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04810962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04810962, "Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04810962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*